Clinical Trials
144 trialsNCT05613088 2026-04-30
A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Bristol-Myers Squibb
Phase 2 Completed
NCT03301350 2026-02-13
Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer
University of Wisconsin, Madison
Phase 2 Completed
NCT05483933 2025-12-23
Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers
Shattuck Labs, Inc.
Phase 1 Completed
NCT02101788 2025-11-13
Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer
National Cancer Institute (NCI)
Phase 2/3 Completed
NCT04209855 2025-08-27
MIRASOL
AbbVie
Phase 3 Completed
NCT00001337 2025-06-22
Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT05567601 2025-06-05
Doxil/Caelyx BE Study
Baxter Healthcare Corporation
Phase 1 Completed
NCT01818063 2025-04-30
Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer
Thomas Jefferson University
Phase 2 Completed
NCT02489903 2025-03-17
RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
EpicentRx, Inc.
Phase 2 Completed
NCT02488564 2025-02-03
met-HEReMYTA
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 2 Completed
NCT00170573 2024-12-16
Caelyx Biweekly in Heavily Pretreated Patients With Relapsed Ovarian Cancer
North Eastern German Society of Gynaecological Oncology
Phase 2 Completed
NCT02312245 2024-12-05
Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Mayo Clinic
Phase 2 Completed
NCT03596281 2024-10-18
PEMBOV
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1 Completed
NCT03164993 2024-10-15
ALICE
Oslo University Hospital
Phase 2 Completed
NCT03409198 2024-10-15
ICON
Oslo University Hospital
Phase 2 Completed
NCT00004112 2024-09-23
Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma
University of Nebraska
Phase 3 Completed
NCT03598270 2024-08-30
ANITA
Grupo Español de Investigación en Cáncer de Ovario
Phase 3 Completed
NCT01696032 2024-08-27
SGI-110
Astex Pharmaceuticals, Inc.
Phase 2 Completed
NCT02606305 2024-06-14
Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer
ImmunoGen, Inc.
Phase 1/2 Completed
NCT03719326 2024-05-24
A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies
Arcus Biosciences, Inc.
Phase 1 Completed
NCT02456857 2024-02-13
Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03907969 2024-02-06
A Clinical Trial to Evaluate AZD7648 Alone and in Combination With Other Anti-cancer Agents in Patients With Advanced Cancers.
AstraZeneca
Phase 1/2 Completed
NCT02483247 2023-11-14
A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer
Sumitomo Pharma America, Inc.
Phase 1 Completed
NCT02206425 2023-10-31
Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients
Oncotherapeutics
Phase 1/2 Completed
NCT02398240 2023-10-26
Brentuximab for Newly Diagnosed Hodgkin Disease
New York Medical College
Phase 2 Completed
NCT00499083 2023-09-29
Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women)
University of Nebraska
Phase 2 Completed
NCT00004197 2023-09-07
Vaccine Therapy Plus Sargramostim Following Chemotherapy in Previously Untreated Aggressive Non-Hodgkin's Lymphoma
University of Nebraska
Phase 2 Completed
NCT01705158 2023-09-06
MYCA
ARCAGY/ GINECO GROUP
Phase 1/2 Completed
NCT02580058 2023-07-10
JAVELIN Ovarian 200
Pfizer
Phase 3 Completed
NCT00258960 2023-04-04
Caelyx, Cyclophosphamide and Herceptin in Patients With Metastatic Breast Cancer
Spanish Breast Cancer Research Group
Phase 2 Completed
NCT04584112 2023-03-15
A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer
Hoffmann-La Roche
Phase 1 Completed
NCT00129389 2023-03-07
FAC Versus FAC Plus Weekly Paclitaxel as Adjuvant Treatment of Node Negative High Risk Breast Cancer Patients
Spanish Breast Cancer Research Group
Phase 3 Completed
NCT00128778 2023-03-06
Maintenance Treatment With Liposomal Doxorubicin (Caelyx) in Metastatic Breast Cancer Patients
Spanish Breast Cancer Research Group
Phase 4 Completed
NCT03639246 2023-02-13
Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer
Aravive, Inc.
Phase 1 Completed
NCT00608972 2023-02-08
Phase II Trial of Doxil, Carboplatin, Bevacizumab in Triple Negative Untreated Metastatic Breast Cancer
Rutgers, The State University of New Jersey
Phase 2 Completed
NCT03161132 2023-01-27
ROLANDO
Grupo Español de Investigación en Cáncer de Ovario
Phase 2 Completed
NCT02186834 2023-01-04
Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Completed
NCT00976131 2022-10-17
Study of CoQ10 During One Cycle of Doxorubicin Treatment for Breast Cancer
Columbia University
Phase 1 Completed
NCT02431559 2022-10-10
Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer
Ludwig Institute for Cancer Research
Phase 1/2 Completed
NCT02865811 2022-09-13
Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01673217 2022-08-01
Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
Roswell Park Cancer Institute
Phase 1 Completed
NCT00976911 2022-06-21
AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer
Hoffmann-La Roche
Phase 3 Completed
NCT01379989 2022-02-09
INOVATYON
Mario Negri Institute for Pharmacological Research
Phase 3 Completed
NCT01445535 2021-11-03
Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00051311 2021-09-09
Modified Stem Cell Transplant Procedure to Treat Patients With Blood and Immune System Cancers
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT02903004 2021-08-25
MITO23
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 3 Completed
NCT01736943 2021-02-24
Bortezomib and Doxil for the Treatment of Patients With Acute Myelogenous Leukemia
University of California, Davis
Phase 2 Completed
NCT00442260 2021-01-22
Doxorubicin HCL Liposome Injection (DOXIL) in Combination With Abraxane in Patients With Metastatic Breast Cancer
West Virginia University
Phase 1/2 Completed
NCT03480750 2020-11-10
Trientine
National Cheng-Kung University Hospital
Phase 1/2 Completed
NCT00101010 2020-10-19
Rituximab and Combination Chemotherapy in Treating Older Patients With Diffuse Large B-Cell Lymphoma
M.D. Anderson Cancer Center
Phase 2 Completed